NCT06655870View on ClinicalTrials.gov

A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2025

Conditions

Healthy Participants

Interventions

DRUG

mRNA-0184

SC injection

Trial Locations (1)

3004

RECRUITING

Nucleus Network, Melbourne

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY